{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:36:08Z","timestamp":1793723768332,"version":"4.6.1"},"reference-count":124,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaci.2025.03.011","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T12:42:49Z","timestamp":1742733769000},"page":"1401-1410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps"],"prefix":"10.1016","volume":"155","author":[{"given":"Radomir","family":"Kratchmarov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Dharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Buchheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2025.03.011_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis 2021","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/lary.23671","article-title":"Symptoms in chronic rhinosinusitis with and without nasal polyps","volume":"123","author":"Dietz de Loos","year":"2013","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2025.03.011_bib3","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.011_bib4","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib5","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jaci.2020.11.037","article-title":"Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps","volume":"147","author":"Klingler","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"10209","key":"10.1016\/j.jaci.2025.03.011_bib6","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2025.03.011_bib7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2025.03.011_bib9","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jaip.2023.12.016","article-title":"Efficacy of EDS-FLU for chronic rhinosinusitis: two randomized controlled trials (ReOpen1 and ReOpen2)","volume":"12","author":"Palmer","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"suppl S29","key":"10.1016\/j.jaci.2025.03.011_bib10","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps, 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2025.03.011_bib11","first-page":"194","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps, 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2025.03.011_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.anai.2021.10.014","article-title":"Yardstick for the medical management of chronic rhinosinusitis","volume":"128","author":"Borish","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib13","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/alr.22851","article-title":"Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps","volume":"11","author":"Han","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib14","first-page":"85","article-title":"The EUFOREA pocket guide for chronic rhinosinusitis","volume":"61","author":"Hellings","year":"2023","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2025.03.011_bib15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/alr.22487","article-title":"Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors","volume":"10","author":"Loftus","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaci.2022.02.029","article-title":"Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps","volume":"150","author":"Bai","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2025.03.011_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1945892420961964","article-title":"Surgery in nasal polyp patients: outcome after a minimum observation of 10 years","volume":"35","author":"Vlaminck","year":"2021","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaip.2019.08.007","article-title":"Asthma is the dominant factor for recurrence in chronic rhinosinusitis","volume":"8","author":"Sella","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.011_bib20","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-exacerbated respiratory disease","volume":"379","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.03.011_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2022.08.021","article-title":"Updates on immune mechanisms in aspirin-exacerbated respiratory disease","volume":"151","author":"Laidlaw","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/lary.23610","article-title":"Role of frontal sinus surgery in nasal polyp recurrence","volume":"123","author":"Bassiouni","year":"2013","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2025.03.011_bib23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2500\/ajr.2006.20.2913","article-title":"Medical and surgical considerations in patients with Samter\u2019s triad","volume":"20","author":"McMains","year":"2006","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib24","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaip.2018.10.014","article-title":"Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting","volume":"7","author":"Benjamin","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.011_bib25","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1111\/all.15222","article-title":"Dupilumab improves health related quality of life: results from the phase 3 SINUS studies","volume":"77","author":"Lee","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib26","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.jaci.2024.07.026","article-title":"Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP","volume":"154","author":"Bachert","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib27","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1111\/all.16189","article-title":"Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis","volume":"79","author":"Bachert","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/19458924241298817","article-title":"Dupilumab treatment for aspirin-exacerbated respiratory disease in a real-world setting: impact on quality of life and healthcare utilization","volume":"39","author":"Mullur","year":"2025","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaci.2024.10.016","article-title":"Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (CHRINOSOR)","volume":"155","author":"Seys","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib31","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1111\/all.16357","article-title":"More than half of chronic rhinosinusitis with nasal polyps (CRSwNP) patients treated with dupilumab experience early and fast olfactory improvement within 28 days","volume":"79","author":"Otten","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib32","first-page":"403","article-title":"Steroid responsiveness predicts olfactory function recovery in dupilumab treated CRSwNP","volume":"62","author":"Otten","year":"2024","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2025.03.011_bib33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.anai.2022.01.036","article-title":"Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease","volume":"128","author":"Miss","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib34","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.011_bib35","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.011_bib36","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2500\/aap.2023.44.230015","article-title":"Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis","volume":"44","author":"Peters","year":"2023","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2025.03.011_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JAA.S420140","article-title":"Dupilumab reduces asthma disease burden and recurrent SCS use in patients with CRSwNP and coexisting asthma","volume":"17","author":"Gurnell","year":"2024","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib39","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1111\/all.16263","article-title":"Real-world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years","volume":"79","author":"Huber","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib40","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jaip.2024.03.011","article-title":"Efficacy of various dosing frequencies of dupilumab in patients with aspirin-exacerbated respiratory disease","volume":"12","author":"Brown","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.011_bib41","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/all.15796","article-title":"Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months","volume":"78","author":"van der Lans","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2500\/aap.2024.45.240047","article-title":"Dupilumab rapidly improves eustachian tube dysfunction and otologic symptoms in aspirin-exacerbated respiratory disease","volume":"45","author":"Mullur","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2025.03.011_bib43","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/alr.23110","article-title":"Effect of dupilumab on eustachian tube dysfunction in patients with chronic rhinosinusitis with nasal polyposis","volume":"13","author":"Chang","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib45","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/19458924211030486","article-title":"Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis","volume":"36","author":"Damask","year":"2022","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib47","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/1945892420972326","article-title":"Effects of omalizumab treatment in patients with recalcitrant nasal polyposis and mild asthma: a multicenter retrospective study","volume":"35","author":"Armengot-Carceller","year":"2021","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaci.2024.11.005","article-title":"Omalizumab safety concerns","volume":"155","author":"Pongdee","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib49","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","article-title":"Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort","volume":"145","author":"Namazy","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.anai.2023.11.001","article-title":"Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status","volume":"132","author":"Gevaert","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00405-019-05650-y","article-title":"Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis","volume":"277","author":"Mostafa","year":"2020","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jaci.2025.03.011_bib52","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaip.2021.09.050","article-title":"Omalizumab-induced aspirin tolerance in nonsteroidal anti-inflammatory drug\u2013exacerbated respiratory disease patients is independent of atopic sensitization","volume":"10","author":"Quint","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.011_bib53","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib54","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib55","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti\u2013IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib56","first-page":"37","article-title":"Improvement in olfaction in patients with CRSwNP and severe asthma taking anti-IgE and anti\u2013IL-5 biologics: a real-life study","volume":"33","author":"Barroso","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib57","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/biomedicines11020485","article-title":"Real-life effectiveness of mepolizumab in refractory chronic rhinosinusitis with nasal polyps","volume":"11","author":"Dom\u00ednguez-Sosa","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaci.2025.03.011_bib58","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaci.2025.03.011_bib59","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1016\/j.jaip.2023.08.015","article-title":"Mepolizumab reduces systemic corticosteroid use in chronic rhinosinusitis with nasal polyps","volume":"11","author":"Chupp","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.011_bib60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/alr.23219","article-title":"Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up","volume":"14","author":"Desrosiers","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib61","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti\u2013IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib62","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib63","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/all.14902","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","volume":"77","author":"Canonica","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib64","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10482","key":"10.1016\/j.jaci.2025.03.011_bib65","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2025.03.011_bib66","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.03.011_bib67","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.03.011_bib68","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2147\/JAA.S413064","article-title":"Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR","volume":"16","author":"Laidlaw","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib69","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib70","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib71","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jaip.2022.02.034","article-title":"Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a network analysis","volume":"10","author":"Cai","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.011_bib72","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.011_bib73","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.jaip.2024.09.015","article-title":"Dupilumab versus mepolizumab for chronic rhinosinusitis with nasal polyposis: an indirect treatment comparison","volume":"12","author":"Hopkins","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.011_bib74","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.jaip.2021.02.020","article-title":"Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti\u2013IL-5 or anti\u2013IL-5R\u03b1 in a real-world setting","volume":"9","author":"Bavaro","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.011_bib75","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.011_bib76","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/alr.23466","article-title":"Switching biologics in chronic rhinosinusitis with nasal polyps: a multicenter Canadian experience","volume":"15","author":"Dorling","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib77","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.anai.2022.01.043","article-title":"Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: efficacy, tolerability, and patient experience","volume":"128","author":"Mullur","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib78","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/1744666X.2023.2218617","article-title":"Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making","volume":"19","author":"Otten","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib79","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4193\/Rhin22.408","article-title":"Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD","volume":"61","author":"Brkic","year":"2023","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2025.03.011_bib80","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/alr.23059","article-title":"A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis","volume":"13","author":"Miglani","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib81","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/alr.22951","article-title":"Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"12","author":"Dharmarajan","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib82","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00405-023-08309-x","article-title":"Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report","volume":"281","author":"Orlando","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jaci.2025.03.011_bib83","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/19458924241272978","article-title":"Comparative effectiveness of dupilumab versus sinus surgery for chronic rhinosinusitis with polyps: systematic review and a meta-analysis","volume":"38","author":"Kim","year":"2024","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib84","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/coa.14172","article-title":"Comparative real-world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients","volume":"49","author":"De Corso","year":"2024","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.jaci.2025.03.011_bib85","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anai.2021.11.020","article-title":"Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease","volume":"128","author":"Patel","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib86","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/alr.22780","article-title":"Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"11","author":"Hopkins","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib87","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2016.05.041","article-title":"Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania","volume":"138","author":"Wang","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"7720","key":"10.1016\/j.jaci.2025.03.011_bib88","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41586-018-0449-8","article-title":"Allergic inflammatory memory in human respiratory epithelial progenitor cells","volume":"560","author":"Ordovas-Montanes","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2025.03.011_bib89","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41590-022-01312-0","article-title":"Single-cell profiling identifies mechanisms of inflammatory heterogeneity in chronic rhinosinusitis","volume":"23","author":"Wang","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib90","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41577-020-0301-x","article-title":"Heterogeneity in the initiation, development and function of type 2 immunity","volume":"20","author":"Gause","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib91","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg6356","article-title":"Single-cell analysis pinpoints distinct populations of cytotoxic CD4+ T cells and an IL-10+CD109+ TH2 cell population in nasal polyps","volume":"6","author":"Ma","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib92","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41590-024-01803-2","article-title":"TCF1-LEF1 co-expression identifies a multipotent progenitor cell (TH2-MPP) across human allergic diseases","volume":"25","author":"Kratchmarov","year":"2024","journal-title":"Nat Immunol"},{"issue":"8050","key":"10.1016\/j.jaci.2025.03.011_bib93","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41586-024-08395-9","article-title":"GZMK-expressing CD8+ T cells promote recurrent airway inflammatory diseases","volume":"638","author":"Lan","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2025.03.011_bib94","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jaci.2020.02.035","article-title":"IL-5R\u03b1 marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease","volume":"145","author":"Buchheit","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib95","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2023.10.011","article-title":"Nasal polyp antibody-secreting cells display proliferation signature in aspirin-exacerbated respiratory disease","volume":"153","author":"Sohail","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib96","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13601-019-0269-4","article-title":"Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis","volume":"9","author":"Calus","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib97","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9\u03b1,11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib98","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A\u00a0randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.03.011_bib99","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jaci.2023.09.041","article-title":"IgE directly affects eosinophil migration in chronic rhinosinusitis with nasal polyps through CCR3 and predicts the efficacy of omalizumab","volume":"153","author":"Yu","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib100","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb7221","article-title":"Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation","volume":"6","author":"Dwyer","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib101","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/alr.23483","article-title":"Real-world predictors of dupilumab prescription in patients with chronic rhinosinusitis with nasal polyps","volume":"15","author":"Dorismond","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib102","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/lary.27564","article-title":"Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size","volume":"129","author":"Laidlaw","year":"2019","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2025.03.011_bib103","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2021.05.043","article-title":"Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib104","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1164\/rccm.202308-1477LE","article-title":"Mepolizumab-induced changes in nasal methylome and transcriptome to predict response in asthma","volume":"209","author":"Rakkar","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.03.011_bib105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in tissue repair and fibrosis","volume":"18","author":"Gieseck","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib106","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1177\/00034894231176334","article-title":"Effect of dupilumab on type 2 biomarkers in chronic rhinosinusitis with nasal polyps: SINUS-52 study results","volume":"132","author":"Bachert","year":"2023","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jaci.2025.03.011_bib107","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/alr.23249","article-title":"Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52","volume":"14","author":"Bachert","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib108","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2025.03.011_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1433","article-title":"Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps","volume":"12","author":"Gevaert","year":"2023","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.jaci.2025.03.011_bib110","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaci.2024.04.020","article-title":"IL-4R\u03b1 signaling promotes barrier-altering oncostatin M and IL-6 production in aspirin-exacerbated respiratory disease","volume":"154","author":"Chen","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib111","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd3489","article-title":"Steroid-resistant human inflammatory ILC2s are marked by CD45RO and elevated in type 2 respiratory diseases","volume":"6","author":"van der Ploeg","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib112","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1111\/all.15877","article-title":"Inflammatory innate lymphoid cells predict response speed to dupilumab in chronic rhinosinusitis with nasal polyps","volume":"78","author":"Golebski","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.011_bib113","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.jaci.2006.01.049","article-title":"Selective downregulation of prostaglandin E2\u2013related pathways by the Th2 cytokine IL-13","volume":"117","author":"Trudeau","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib114","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaci.2024.05.030","article-title":"Nasal brushing molecular endotyping distinguishes patients with chronic rhinosinusitis with nasal polyps with better response to dupilumab","volume":"154","author":"Gayvert","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib115","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaci.2024.04.020","article-title":"IL-4R\u03b1 signaling promotes barrier-altering oncostatin M and IL-6 production in aspirin-exacerbated respiratory disease","volume":"154","author":"Chen","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib116","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.jaci.2016.10.039","article-title":"Neutrophils are a major source of the epithelial barrier disrupting cytokine oncostatin M in patients with mucosal airways disease","volume":"139","author":"Pothoven","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib117","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jaci.2022.11.029","article-title":"Evidence that oncostatin M synergizes with IL-4 signaling to induce TSLP expression in chronic rhinosinusitis with nasal polyps","volume":"151","author":"Wang","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib118","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.011_bib119","first-page":"287","article-title":"EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP","volume":"62","author":"Fokkens","year":"2024","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2025.03.011_bib120","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/lary.28648","article-title":"Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal Polyps","volume":"131","author":"Scangas","year":"2021","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2025.03.011_bib121","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/alr.22936","article-title":"Economic evaluation of dupilumab versus endoscopic sinus surgery for the treatment of chronic rhinosinusitis with nasal polyps","volume":"12","author":"Parasher","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib122","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/alr.22976","article-title":"Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population","volume":"12","author":"Rathi","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib123","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/alr.23344","article-title":"The Inflation Reduction Act: implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma","volume":"14","author":"Rathi","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.011_bib124","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/alr.23246","article-title":"Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP)","volume":"14","author":"Garvey","year":"2024","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925003264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925003264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:31:24Z","timestamp":1777264284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674925003264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0091674925003264"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2025.03.011","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2025.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}